Health ❯Healthcare ❯Pharmaceuticals ❯Drug Approval

FDA Approval

FDA Approves Lurbinectedin Plus Atezolizumab for First-Line Maintenance in Extensive-Stage SCLC

The decision follows phase 3 data showing the regimen extends progression-free and overall survival compared with atezolizumab alone.

FDA Approves Lilly’s Inluriyo for ESR1‑Mutated Advanced Breast Cancer

FDA Grants Accelerated Approval to Forzinity, First Therapy for Barth Syndrome